Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jun 7;6(2):22.
doi: 10.3390/diagnostics6020022.

Surveillance for Hepatocellular Carcinoma in Patients with NASH

Philippe Kolly  1   2 , Jean-François Dufour  3   4
Affiliations
Review

Surveillance for Hepatocellular Carcinoma in Patients with NASH

Philippe Kolly et al. Diagnostics (Basel). .

Abstract

European and American guidelines recommend surveillance for hepatocellular carcinoma (HCC) by performing ultrasonography on a six-month basis on an at risk population, defined by presence of cirrhosis. HCC, due to non-alcoholic steatohepatitis (NASH), is rising. Patients with NASH have a high risk of developing HCC and, therefore, have to be enrolled in a screening program. One of the challenges with NASH-induced HCC is that half of the cases arise in non-cirrhotic patients. There is a need to identify those patients in order to screen them for HCC. The obesity of these patients is another challenge, it makes ultrasound screening more difficult. Other radiological methods, such as computer tomography (CT) scans or magnetic resonance imaging (MRI), are available, but the surveillance program would no longer be cost-effective. There is a need to prospectively acquire information on cohorts of patients with NASH in order to improve the tools we have to diagnose early tumors in these patients.

Keywords: HCC; NAFLD; NASH; screening; surveillance.

PubMed Disclaimer

References

    1. Bruix J., Sherman M. Management of hepatocellular carcinoma: An update. Hepatology. 2011;53:1020–1022. doi: 10.1002/hep.24199. - DOI - PMC - PubMed
    1. European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer Easl–eortc clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2012;56:908–943. - PubMed
    1. Zhang B.H., Yang B.H., Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2004;130:417–422. doi: 10.1007/s00432-004-0552-0. - DOI - PMC - PubMed
    1. Chen J.G., Parkin D.M., Chen Q.G., Lu J.H., Shen Q.J., Zhang B.C., Zhu Y.R. Screening for liver cancer: Results of a randomised controlled trial in qidong, china. J. Med. Screen. 2003;10:204–209. doi: 10.1258/096914103771773320. - DOI - PubMed
    1. Singal A.G., Pillai A., Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: A meta-analysis. PLoS Med. 2014;11:22. doi: 10.1371/journal.pmed.1001624. - DOI - PMC - PubMed